Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.45 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.41 |
| ▸ | SLC10A1 | Q14973 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | WRN | Q14191 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30093996 | 0.92 | GRM4 (0.48) | GRM4LRRK2IMPDH2SLC10A1LMNA | |
| SCHEMBL30093984 | 0.92 | GRM4 (0.52) | GRM4LRRK2IMPDH2SLC10A1KDM4E | |
| SCHEMBL21428173 | 0.92 | GRM4 (0.52) | GRM4LRRK2IMPDH2SLC10A1KDM4E | |
| SCHEMBL30294224 | 0.88 | GRM4 (0.52) | GRM4LRRK2IMPDH2SLC10A1KDM4E | |
| SCHEMBL21810315 | 0.85 | ALDH1A1 (0.42) | KDM4EALDH1A1POLBHPGDHSD17B10 | |
| SCHEMBL30094027 | 0.83 | GRM4 (0.43) | GRM4LRRK2IMPDH2SLC10A1BLM | |
| SCHEMBL30094008 | 0.82 | GRM4 (0.43) | GRM4LRRK2IMPDH2SLC10A1AR | |
| SCHEMBL23010405 | 0.81 | GRM4 (0.48) | GRM4LRRK2SLC10A1KDM4EALDH1A1 | |
| SCHEMBL21428163 | 0.81 | GRM4 (0.48) | GRM4LRRK2SLC10A1KDM4EALDH1A1 | |
| SCHEMBL22564872 | 0.80 | GRM4 (0.52) | GRM4LRRK2IMPDH2SLC10A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4036078-B1 | CRYSTALLINE FORMS OF A CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING A PYRROLE RING, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD (CN) | 2026-02-11 | — | — | EP | disclosed |
| US-12378192-B2 | Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| CN-114430736-B | Crystal form of capsid protein assembly inhibitor containing N-hetero five-membered ring and application thereof | 正大天晴药业集团股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-12116356-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-10-15 | — | — | US | disclosed |
| US-20230212117-A2 | CRYSTALLINE FORM OF CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N HETERO FIVE-MEMBERED RING, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212117-A2 | CRYSTALLINE FORM OF CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N HETERO FIVE-MEMBERED RING, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212117-A2 | CRYSTALLINE FORM OF CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N HETERO FIVE-MEMBERED RING, AND APPLICATION THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-06-15 | — | — | US | disclosed |
| CN-115974754-A | N-containing heterocyclic five-membered ring compound and application | 正大天晴药业集团股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2021119081-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021119081-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021058002-A1 | CRYSTALLINE FORM OF CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N HETERO FIVE-MEMBERED RING, AND APPLICATION THEREOF | 正大天晴药业集团股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021058002-A1 | CRYSTALLINE FORM OF CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N HETERO FIVE-MEMBERED RING, AND APPLICATION THEREOF | 正大天晴药业集团股份有限公司 | 2021-04-01 | — | — | WO | disclosed |
| EP-3778569-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778569-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210017154-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| US-20210017154-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| CN-111868026-A | Capsid protein assembly inhibitor containing N-heterocyclic five-membered ring, pharmaceutical composition and application thereof | 正大天晴药业集团股份有限公司 | 2020-10-30 | — | — | CN | disclosed |
| WO-2019185016-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 正大天晴药业集团股份有限公司 | 2019-10-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378192-B2 | Crystalline form of capsid protein assembly inhibitor containing N hetero five-membered ring, and application thereof | COPB1, RPL35, ZC3HAV1 | GRM4 4293/4885LRRK2 1298/4885IMPDH2 3428/4885 |
| US-20230212117-A2 | CRYSTALLINE FORM OF CAPSID PROTEIN ASSEMBLY INHIBITOR CONTAINING N HETERO FIVE-MEMBERED RING, AND APPLICATION THEREOF | COPB1, RPL35, ZC3HAV1 | GRM4 4293/4885LRRK2 1298/4885IMPDH2 3428/4885 |
| US-12116356-B2 | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | COG5, HAVCR2, ZC3HAV1 | GRM4 4715/4885LRRK2 1174/4885IMPDH2 2637/4885 |
| US-20230183208-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | COG5, HAVCR2, ZC3HAV1 | GRM4 4715/4885LRRK2 1174/4885IMPDH2 2637/4885 |
| US-20210017154-A1 | N-HETEROCYCLIC FIVE-MEMBERED RING-CONTAINING CAPSID PROTEIN ASSEMBLY INHIBITOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | COG5, HAVCR2, ZC3HAV1 | GRM4 4715/4885LRRK2 1174/4885IMPDH2 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.